3SBio Inc. — Capital/Financing Update 2022

Jan 4, 2022

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

==> picture [110 x 133] intentionally omitted <==

(Incorporated in the Cayman Islands with limited liability) (Stock Code: 1530)

VOLUNTARY ANNOUNCEMENT SUNSHINE GUOJIAN TO ENTER INTO A LICENSING PARTNERSHIP WITH SYNCROMUNE TO DEVELOP AND COMMERCIALIZE IMMUNO-ONCOLOGY COMBINATION THERAPY USING ANTI-PD-1 ANTIBODY 609A

3SBio Inc. (the “ Company ”) wishes to inform the shareholders of the Company of the attached press release regarding the entering into of a licensing agreement by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (“ Sunshine Guojian ”), a subsidiary of the Company with Syncromune, a biopharmaceutical company headquartered in the United States, to develop and commercialize Sunshine Guojian’s anti-PD-1 antibody 609A for use with syncrovax™ immunooncology combination therapy worldwide. Pursuant to the agreement, Sunshine Guojian has the potential to receive hundreds of millions of US dollars in payments, including an upfront cash payment that reflects the projected clinical value of the PD-1 molecule, significant regulatory and sales milestones and other incentives based on the long-term commercial value of the patented PD-1 molecule.

This is a voluntary announcement made by the Company. The Company cannot guarantee that it is able to successfully develop or eventually launch and/or commercialize such product. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board 3SBio Inc. Dr. LOU Jing Chairman

Shenyang, the PRC 4 January 2022

As at the date of this announcement, the Board comprises Dr. LOU Jing and Ms. SU Dongmei as executive Directors; Mr. HUANG Bin and Mr. TANG Ke as non-executive Directors; and Mr. PU Tianruo, Dr. WONG Lap Yan and Ms. YANG Hoi Ti Heidi as independent non-executive Directors.

1

==> picture [111 x 18] intentionally omitted <==

==> picture [111 x 17] intentionally omitted <==

Press release

SYNCROMUNE AND SUNSHINE GUOJIAN, A SUBSIDIARY OF 3S BIO INC., TO ENTER INTO A LICENSING PARTNERSHIP TO DEVELOP AND COMMERCIALIZE IMMUNO-ONCOLOGY COMBINATION THERAPY USING ANTI-PD-1 ANTIBODY 609A

(January 4, 2022, Shanghai, China) 3SBio Inc. (01530.HK), one of the leading biopharmaceutical companies in China today announced the entering into of a licensing agreement between Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (stock code: 688336) (“ Sunshine Guojian ”), a subsidiary of 3SBio Inc., and Syncromune, a biopharmaceutical company headquartered in the United States, to develop and commercialize Sunshine Guojian’s anti-PD-1 antibody 609A for use with syncrovax™ immuno-oncology combination therapy worldwide. As part of the partnership, Sunshine Guojian has the potential to receive hundreds of millions of US dollars in payments, including an upfront cash payment that reflects the projected clinical value of the PD-1 molecule, significant regulatory and sales milestones and other incentives based on the long-term commercial value of the patented PD-1 molecule. YAFO Capital (Shanghai) acted as exclusive financial advisors on this transaction for Syncromune.

Under the terms of the agreement, Syncromune will acquire the global development and commercialization right of 609A for its syncrovax™ immuno-oncology therapy. Milestone payments and royalties will be based on syncrovax™ total sales. Sunshine Guojian still holds all the global rights beyond syncrovax™.

609A is an anti-PD-1 antibody developed by Sunshine Guojian, phase 1 trial in the United States has been finished and phase 2 trial in China is ongoing. Public documents show that 609A has stronger anti-tumor potency than Keytruda and Opdivo in animal models.

According to preclinical studies, 609A has explicit molecular structure, good DP stability and activity, PK/PD results equal or outperform other drugs in the same class. “609A is the first innovative drug product of 3SBio Inc. to go overseas. We are very happy to cooperate with Syncromune. This transaction will not only bring cash flow and income to the company, but also it will have a positive impact on 609A’s future cooperation with foreign countries and domestic clinical research and registration approval, and at the same time demonstrates R&D strength of 3SBio Inc..” said Dr. LOU Jing, Chairman of 3SBio Inc..

2

==> picture [111 x 18] intentionally omitted <==

==> picture [111 x 17] intentionally omitted <==

About 609A

609A is an anti-PD-1 humanized monoclonal antibody developed by Sunshine Guojian. It targets the same target with two imported drugs (Keytruda and Opdivo), but has different amino acid sequences. In the humanized PD-1 mouse model, it showed stronger tumor activity than Keytruda and Opdivo. The results of in vivo and in vitro comparisons indicate that SSGJ-609A is similar to the two imported drugs in terms of biological activity, efficacy, pharmacokinetics, etc.; preclinical research results show that 609A has a clear molecular structure and good product stability, Drug activity, animal pharmacokinetics (PK)/pharmacodynamics (PD) have reached or surpassed similar foreign drugs.

About 3SBio Inc.

3SBio Inc. is a leading biopharmaceutical company integrating research and development (“ R&D ”), production and sales, with a focus on improving the life quality of patients with highquality medicines to benefit human health. At present, the Company owns more than 100 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, including, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Company owns four R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 35 kinds of products under R&D, 24 kinds of which are innovative new drugs. The Group also owns five production bases complying with the GMP standards. In the future, 3SBio Inc. will continue to uphold the concept of “Care for Life, Cherish Life, Create Life” to create a world-leading biopharmaceutical company in China. Please visit www.3sbio.com for additional information.

About Syncromune

Syncromune is an innovative biopharmaceutical company headquartered in the United States, focusing on the development of a new generation of tumor immunotherapy for intratumoral drug delivery. The core technology syncrovax™ therapy is a personalized autologous vaccine platform intended to overcome the immunosuppressive properties of metastatic cancer to solve the limitations of current systemic immunotherapy, so as to achieve the purpose of treating a variety of solid tumors.

3

==> picture [111 x 18] intentionally omitted <==

==> picture [111 x 17] intentionally omitted <==

About YAFO Capital

YAFO Life Sciences (“ YLS ”) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and medtech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For additional information regarding YAFO, please visit www.yafocapital.com

Cautionary Note and Forward-Looking Statements

This press release contains forward-looking statements, such as those relating to business or products outlook, or the Company’s intent, plans, beliefs, expectation and strategies. These forward-looking statements are based on information currently available to the Company and are stated herein on the basis of the outlook at the time of this press release. They are based on certain expectations, assumptions and premises, some of which are subjective or beyond our control. These forward-looking statements may prove to be incorrect or may not be realized in the future. With respect to any new product or new indication, we cannot guarantee that we will be able to successfully develop or eventually launch and market such product or indication. Underlying the forward-looking statements is a large number of risks and uncertainties. Further information regarding such risks and uncertainties may be found in our other public disclosure documents. The scientific information involved may only be preliminary and empirical. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

4